FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
What happened
FDA reviewed the website https://www.vivrx.com in December 2025 and found it offers compounded semaglutide and tirzepatide drug products. The labels pictured on the site show "VIV RX," which suggests VIV RX is the compounder of those drugs when it is not. FDA says those representations are false or misleading, so the products are misbranded.
What FDA found
The website labels name VIV RX as if it made the compounded drugs, when it did not, which makes the labeling false or misleading.
FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)Advertising or promoting a compounded drug with false or misleading claims misbrands that drug.
FDCA § 502(bb) [21 U.S.C. § 352(bb)]Sending these misbranded drugs across state lines is a prohibited act.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]The semaglutide and tirzepatide products are "new drugs" not generally recognized as safe and effective, and compounded drugs must meet the conditions of section 503A or 503B to be exempt from new drug approval requirements.
FDCA §§ 201(p), 503A, 503B [21 U.S.C. §§ 321(p), 353a, 353b]
What FDA wants
Within 15 working days, VIV RX must send a written response to FDA's Office of Compounding Quality and Compliance describing the steps taken to fix the violations and prevent recurrence. The response should identify who actually produces the compounded products, include sample labeling, and address or correct the other website claims.
Who should pay attention
- telehealth platforms that market compounded semaglutide and tirzepatide
- compounding pharmacies whose products are sold under a marketer's name
- marketers and brands that put their own name on drug labels they do not manufacture
This is a summary. Read the original letter on fda.gov.